Lupin plans to expand footprint in Europe

17 Jun 2014 Evaluate

Lupin is planning to expand its footprint in Europe by acquiring generics manufacturers for as much as $1 billion. The company is eying those entities that are capable in complex generics like inhalation products and injectables, dermatology products and biosimilar drugs.

Europe is attractive because it has clearer regulations than the US on biosimilars, or copies of biotechnology therapies. Europe contributed 3 percent of Lupin’s sales last year.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.

Lupin Share Price

2112.95 3.95 (0.19%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×